

PHASE III TARGET: STROKESM



American Heart Association.
Target: Stroke

Target: Stroke Phase III Door-to-Device Time Key Best Practice Strategies

Target: Stroke advocates the adoption of these 12 key best practice strategies for reducing door-to-device times for endovascular therapy in acute ischemic stroke.

1. **Rapid Administration of Alteplase:** Follow Target: Stroke Phase I and II Key Best Practice Strategies for rapid assessment, diagnostic imaging, and, if indicated, administration of alteplase: EMS prenotification, stroke toolkits, rapid triage and stroke team notification, single call activation system, transfer directly to CT scanner, rapid acquisition of brain imaging, rapid laboratory testing (when indicated), mix alteplase ahead of time, rapid access and administration of alteplase, administration of alteplase bolus and start infusion on the imaging table, team-based approach, prompt data feedback.¹⁻⁴
2. **Rapid Acquisition and Interpretation of CT/MR Angiography:** In addition to non-contrast CT (NCCT) (or MR) brain scan, CT (or MR) angiography should be performed in all stroke patients who meet an institutional threshold for clinical stroke severity. The use of any advanced imaging beyond NCCT (or MR) should not delay the administration of intravenous alteplase in eligible patients. Vascular imaging should be performed at the same sitting as the NCCT (or MR) with alteplase decision and administration on the imaging table.^{5,6}
3. **Rapid Acquisition and Interpretation of Additional Imaging:** Additional imaging techniques, particularly those intended to physiologically select patients for endovascular therapy (CT perfusion penumbral imaging, MR diffusion-perfusion penumbral imaging, dynamic CTA collateral imaging), are of likely benefit in patients 6-24 hours, but uncertain benefit in patients 0-6 hours, from last known well. If obtained, additional imaging should be performed and interpreted rapidly, and not delay administration of intravenous alteplase or endovascular therapy.^{5,6}
4. **Pre-Notification and Rapid Activation of the Neurointerventional Team:** Acute triage protocols facilitate the timely recognition of acute ischemic stroke patients that may benefit from endovascular therapy and reduce time to treatment. The neurointerventional team should be activated by a single paging system as soon as a possible candidate for thrombectomy is identified based upon a pre-specified clinical severity threshold or imaging suggesting the potential for large vessel occlusion. If a patient is being transferred for potential endovascular therapy, the neurointerventional team should receive pre-notification.^{5,6}
5. **Rapid Availability of the Neurointerventional Team:** The hospital should have a policy in place specifying the expected arrival times to the neuroangiography suite (preferably ≤ 30 minutes) that the neurointerventional team on call (neurointerventionalist, interventional technologist, nurses) need to fulfill.⁷
6. **Timer or Clock Attached to Chart, Clip Board, or Bed.** Acute ischemic stroke care including endovascular therapy requires an accurate, timely, coordinated and systematic evaluation of the patient. A universal clock visible to the stroke and neurointerventional team is an enabling tool for improving the timeliness and quality of care and should be considered for recording critical stages.³
7. **Transfer Directly to Neuroangiography Suite:** Guided by prespecified protocols eligible stroke patients who are being transferred can, if appropriate (based on recent brain and vascular imaging with no change to clinical status), be transported directly to the neuroangiography suite. Written protocols with explicit inclusion/exclusion criteria should be in place to ensure that patients requiring emergency medical assessment or stabilization are not directly triaged to the neuroangiography suite. Alternatively, rapid assessment by the Emergency Medicine Physician while the patient remains on the EMS transport gurney can be performed to ensure hemodynamic/ respiratory stability and to evaluate for other emergency diagnoses followed by transport to the neuroangiography suite.⁵

TIME LOST IS BRAIN LOST.
Learn more at [Stroke.org/TargetStroke](https://stroke.org/TargetStroke).

Genentech is a National Supporter of the American Heart Association's Target Stroke – Phase III



American Heart Association.
Get with the Guidelines.
Stroke

PHASE III TARGET: STROKESM



American Heart Association.
Target: Stroke

8. **Transfer Directly from Brain Imaging Suite to Neuroangiography Suite:** Stroke patients eligible for endovascular therapy should be directly transported from the CT/MR imaging suites to the neuroangiography suite, if ready to receive the patient, without returning to the Emergency Department.⁵
9. **Endovascular Therapy Ready Neuroangiography Suite:** Have policies and protocols in place to have the neuroangiography suite in an endovascular therapy ready state at all times. This includes standardized, pre-prepared equipment tray/cart for endovascular therapy cases that includes all necessary equipment for the case (e.g. BRISK: Brisk Recanalization Ischemic Stroke Kit, with drapes, tubing, syringes, catheters, and devices). Institutions should have a standardized endovascular technique as a first line approach to endovascular therapy (consensus between all operators) so that the nursing staff do not have to vary equipment/tools based on the person on call.⁶⁻⁹
10. **Team Based Approach:** Parallel workflows by Emergency Department Team, stroke team, and neurointerventional team, including the neurointerventionalists, interventional technologists, and nursing staff, should be utilized to facilitate rapid performance of invasive imaging and when indicated endovascular therapy.⁵⁻⁸
11. **Anesthesia Access and Protocols:** Rapid availability and access to anesthesiology, when clinically indicated. Conscious sedation may be used in non-agitated compliant patients. If general anesthesia is employed, induction should be swift and done without allowing a drop in blood pressure and in a way to minimize any delay to procedure start. These workflow recommendations should be tailored to meet the needs of individual institutions.^{6,10,11}
12. **Prompt Data Feedback:** Accurately measuring and tracking your hospital's door-to-device times, other time intervals, and performance on other stroke performance/ quality measures for endovascular therapy allow the neurointerventional and stroke teams to identify areas for improvement and take appropriate action. A data monitoring and feedback system such as the Get With The Guidelines-Stroke Patient Management Tool creates a process for providing timely feedback and recommendations for improvement on a case-by-case basis and in hospital aggregate. This system helps identify specific preventable delays, devise strategies to overcome them, set targets, and monitor progress on a case-by-case basis.^{2,3,12}

References

1. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, Sacco RL, Schwamm LH. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. *Stroke*. 2011;42:2983-2989.
2. Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. *JAMA*. 2014;311:1632-1640.
3. Xian Y, Xu H, Lytle B, Blevins J, Peterson ED, Hernandez AF, Smith EE, Saver JL, Messe SR, Paulsen M, Suter RE, Reeves MJ, Jauch EC, Schwamm LH, Fonarow GC. Use of strategies to improve door-to-needle times with tissue-type plasminogen activator in acute ischemic stroke in clinical practice: findings from Target: Stroke. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003227. doi:10.1161/CIRCOUTCOMES.116.003227.
4. Menon, B. K., Xu, H., Cox, M., Saver, J. L., Goyal, M., Peterson, E. D., . . . Smith, E. E. (2018, September 21). Components and Trends in Door to Treatment Times for Endovascular Therapy in GWTG-Stroke Hospitals. *Circulation*. Retrieved from <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.036701>.
5. Sun CH, Bhatt DL, Nogueira RG, Gupta R. Endovascular therapy for stroke: getting to the "heart" of the matter. *Circulation*. 2014 Mar 11;129(10):1152-60. doi:10.1161/CIRCULATIONAHA.113.003703.
6. McTaggart, R. A., Ansari, S. A., Goyal, M., Abruzzo, T. A., Albari, B., Arthur, A. J., . . . Jayaraman, M. V. (2017). Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery. *Journal of NeuroInterventional Surgery*. 9, 316-323. doi:10.1136/neurintsurg-2015-011984.
7. McTaggart, R. A., Yaghi, S., Baird, G., Haas, R. A., & Jayaraman, M. V. (2017). Decreasing procedure times with a standardized approach to ELVO cases. *Journal of NeuroInterventional Surgery*(9), 2-5. Retrieved from <https://jn.is.bmj.com/content/neurintsurg/9/1/2.full.pdf>.
8. Settecase, F., McCoy, D. B., Darflinger, R., Alexander, M. D., Cooke, D. L., Dowd, C. F., . . . Amans, M. R. (2017, November 16). Article Menu. *Interventional Neuroradiology*, 24(2), 168-177. doi:10.1177/1591019917742326.
9. Frei D, McGraw C, McCarthy K, et al. A standardized neurointerventional thrombectomy protocol leads to faster recanalized times. *J NeuroIntervent Surg* 2017;9:1035-1041. doi:10.1136/neurintsurg-2016-012716.
10. Purucker JC, Nagel S, Klose CZ, Pfaff J, Bendszus M, Ringleb PA, Kieser M, Möhlenbruch MA, Bösel J (2016) November 15). Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy. *JAMA*. 316(19):1986-1996. doi: 10.1001/jama.2016.16623.
11. Menon, B. K., Sajobi, T. T., Zhang, Y., Rempel, J. L., Shuaib, A., Thornton, J., . . . Goyal, M. (2016, April 13). Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled Trial. *Circulation*, 133(23), 2279-2286. doi:10.1161.
12. Kamal, N., Smith, E. E., Menon, B. K., Eesa, M., Ryckborst, K. J., Poppe, A. Y., . . . Hill, M. D. (2017). Improving reperfusion time within the ESCAPE endovascular clinical trial. *European Stroke Journal*, 2(1), 64-69. Retrieved from <https://journals.sagepub.com/doi/pdf/10.1177/2396987316681176>.

Additional References:

Kim DH, Kim B, Jung C, et al. Consensus Statements by Korean Society of Interventional Neuroangiography and Korean Stroke Society: Hyperacute Endovascular Treatment Workflow to Reduce Door-to-Reperfusion Time. *J Korean Med Sci* 2018; Sep-Oct;19(5):838-848. doi: 10.3348/kjr.2018.19.5.838.

Bourcier R, Goyal M, Liebeskind DS, et al. Association of Time From Stroke Onset to Groin Puncture With Quality of Reperfusion After Mechanical Thrombectomy: A Meta-analysis of Individual Patient Data From 7 Randomized Clinical Trials. *JAMA Neurol*. 2019 Jan 22. doi: 10.1001/jamaneurol.2018.4510.

TIME LOST IS BRAIN LOST.
Learn more at Stroke.org/TargetStroke.

Genentech is a National Supporter of the American Heart Association's Target Stroke – Phase III



American Heart Association.
Get with the Guidelines.
Stroke